Lukman Bello, a doctoral researcher at Purdue University, has made significant strides in cancer therapeutics with his latest study on novel PDE5 inhibitors for targeted colorectal cancer treatment. His research, recently published in a leading scientific journal, highlights the potential of a redesigned compound, MS01, which aims to provide a safer and more effective alternative to existing treatments.
Optimizing Cancer Treatment Through Advanced Computational Techniques
Bello’s work focuses on the rational design of new PDE5 inhibitors, using cutting-edge computational techniques to optimize their effectiveness while minimizing toxicity. His research underscores the critical role of chemistry in drug development, particularly in creating targeted therapies with improved safety profiles.
At the core of his study is MS01, a modified version of Exisulind, an anti-cancer compound previously discontinued due to liver toxicity. By leveraging molecular docking and dynamic simulations, Bello and his team successfully enhanced MS01’s efficacy while reducing its toxic effects.
A Promising Step Toward Safer Colorectal Cancer Therapies
Preliminary findings indicate that MS01 binds strongly to key PDE5 residues, demonstrating favorable pharmacokinetic properties such as enhanced bioavailability and a lower risk of drug interactions. Further toxicity profiling also confirmed that MS01 and its analogues, MS20 and MS21, exhibit significantly reduced hepatotoxicity compared to Exisulind.
“By integrating analytical chemistry for compound characterization, organic chemistry for structural design, and computational chemistry for predictive modeling, this approach enables faster and more precise development of safer and more effective therapies,” Bello explained.
Expanding Research Beyond Colorectal Cancer
Beyond colorectal cancer, Bello is applying similar computational strategies to develop new ligands for HIV treatment. His multidisciplinary approach, which combines chemistry and computational modeling, is accelerating drug discovery across multiple disease areas.
“This research is a testament to how strategic applications of chemistry can drive progress in global health, reduce treatment toxicity, and improve patient outcomes,” he added.
While the results are promising, further laboratory validation is required before MS01 can advance to clinical trials. If successful, it could pave the way for a new generation of colorectal cancer treatments with improved safety and efficacy.
Leave a Reply